Regarding Five with The Pouch (and Seven the maximum number) rather than many more... The Pouch is a medical device and not a drug. As such, one doesn't need to show the device works in as many people as you would a drug.
Generally, if a device works in a few people with no adverse consequences, and Sernova has demonstrated this unequivocally, then it will work period with the general population with no adverse consequences.
There are two sides with this FDA trial. The first is to answer: is it a safe device? In fact, in the submission for the trial, Sernova was already able to supply that kind of data. Then, during the trial with each Cohort (5), it was able to show the device is safe. With safety a non-issue, the second side is will it work to help, or better yet, functionally cure the most difficult to treat diabetics on the planet? The last news release, answered that with an unequivocal yes!
Sernova has demonstrated that The Pouch, as a medical device, is both safe and it will functionally cure the hardest to treat diabetics on this planet. This is why I emphasize World First and World Class. No other entity is even close to what Sernova has been able to do with diabetes.
Only now, is "Big Pharma" starting to understand what Sernova has. The extension of the warrants for three months is a clear signal that the "Behind the Scenes Pot" is boiling nicely.
Unfortunately, for we shareholders, trading activity has been insufficient to overcome the computers doing their thing with SVA. This is both frustrating and disheartening. Disgruntled shareholders start making up all sorts of unsubstantiated stories in their vivid imagination and voicing same. There are two problems with this [rather than waiting some more (yes, painful, I know)]. The first is that it tends to discourage new money from entering and also promotes churning of the stock for a few cents gain (usually by the computers AND they are able to detect this from trading patterns).
In fact, I suggest today's action reflects these sentiments. The general markets were euphoric whereas SVA made a half cent tango down to close at $0.28 on a small 189k (74k Germany; 18k US). "017" was busy handling the computers as seen by the large number of 500 share lot trades, but a relatively small volume, sic.
In closing, we must remember that share price has little correlation with news (until it does, i.e. Deep Pockets decide to enter the trading). Trillium (TRIL - TSX) is a perfect example. In addition, what is happening behind the scenes becomes known only after the fact. In other words, Dr. Toleikis (who has already been a major facilitator of a significant Buy, Bye) is working diligently for all shareholders to drag something across the finish line. The three month warrants extension is a clear signal to all.